Nikhil Prasad Fact checked by:Thailand Medical News Team Apr 12, 2026 1 hour, 47 minutes ago
Medical News: A new scientific investigation has uncovered a significant molecular mechanism behind a common yet often troubling jaw tumor known as ameloblastoma, offering hope for more targeted and less invasive treatments in the future. The study reveals that a gene called FGFR2 is highly active in most of these tumors, potentially playing a central role in their growth and persistence.
Researchers uncover FGFR2 gene disruptions as a major factor in aggressive jaw tumor development
Understanding a Silent but Aggressive Tumor
Ameloblastoma is a tumor that develops in the jaw, most frequently in the lower jaw or mandible. Although it is considered benign, it behaves aggressively at the local level, gradually destroying surrounding bone and tissue. Many patients require extensive surgery, which can lead to facial deformities and long-term functional issues.
Scientists have been working to understand the biological factors driving this tumor. The latest research now highlights FGFR2, a gene involved in regulating cell growth, as a major contributor.
Key Findings Reveal Widespread Gene Overactivity
The research team examined 87 tumor samples and found that FGFR2 was overexpressed in 95.4 percent of cases, indicating that the gene was significantly more active than normal in nearly all tumors analyzed. In contrast, healthy tissue samples showed no such activity, reinforcing the gene’s link to disease.
Further analysis revealed that 52.5 percent of tumors had FGFR2 gene amplification, meaning extra copies of the gene were present. Additionally, 8.2 percent showed gene deletion. Despite these differences, both alterations were associated with increased FGFR2 activity, suggesting that any disruption of this gene may promote tumor development.
What Makes This Discovery Important
One of the most notable findings is that FGFR2 overexpression was not linked to patient age, gender, tumor size, or recurrence history. This indicates that FGFR2 likely plays a fundamental role in the biology of the tumor itself rather than being influenced by external factors.
However, a significant association was found between FGFR2 amplification and tumor imaging features. Tumors appearing as single-chamber lesions were more likely to show gene amplification, suggesting that FGFR2 may be involved in early tumor formation.
Potential for Targeted Treatments
This
Medical News report highlights that FGFR2 may serve as an important target for future therapies. Current treatment approaches rely heavily on surgical removal, often requiring wide excision to reduce recurrence risk. While effective, such procedures can be highly invasive.
Emerging evidence suggests that drugs designed to inhibit FGFR2 activity may help shrink tumors. Although still under investigation, these therapies could eventually offer patients less invasive alternatives with improved outcomes.
>
Researchers and Institutions Behind the Study
The study was conducted by researchers from the following institutions: Faculty of Dentistry, Chiang Mai University; Faculty of Dentistry, Burapha University; Department of Oral and Maxillofacial Pathology, Faculty of Dentistry, Mahidol University; Faculty of Dentistry, Nation University; and the Faculty of Medicine, Chulalongkorn University, Thailand.
Expanding the Scientific Understanding
The researchers also observed that some tumors showed FGFR2 overexpression without gene amplification or deletion. This suggests additional mechanisms, such as gene mutations, may also contribute to abnormal activity. Further studies are ongoing to explore these pathways.
There is also growing interest in how FGFR2 interacts with other cancer-related genes, which could open the door to combination treatments targeting multiple pathways at once.
Conclusion
The study provides compelling evidence that FGFR2 plays a central role in the development of mandibular ameloblastoma. By demonstrating that both gene amplification and deletion can lead to increased activity, the findings highlight the complexity of tumor biology while reinforcing FGFR2 as a promising therapeutic target. Although more research is needed before these discoveries translate into routine clinical treatments, the implications are significant. Future therapies targeting FGFR2 could reduce reliance on invasive surgeries and improve both functional and cosmetic outcomes for patients. Ultimately, this research represents an important step toward more precise and patient-friendly management of jaw tumors.
The study findings were published in the peer reviewed International Journal of Molecular Sciences.
https://www.mdpi.com/1422-0067/27/8/3443
For the latest medical study conducted by Thai researchers, keep on logging to
Thailand Medical News.
Read Also:
https://www.thailandmedical.news/articles/thailand-medical
Share
Tweet
Share
